American Urological Association 2019

SmartTarget attended the American Urological Association conference in Chicago, USA this past week to meet with a range of companies with whom we are forging growing partnerships especially in the focal therapy arena. Companies ranging from Sonacare (whose Sonablate system we integrated with a couple of years ago) to new innovators like MediFocus (who are adapting their pioneering thermal ablation technology for use in focal therapy and whose CEO William Jow hosted SmartTarget – see photo).

Perhaps the most encouraging news at the event was the strong consensus that the USA market needs to move away from TR biopsy to TP. TR has dominated for years with clinicians compensating for the risks of infection with routine prescriptions of follow-up antibiotic regimes. But the significant number of complications which arise anyway as well as the growing sensitivity to antibiotic resistance from over-use is driving the intensified consensus and push toward TP.